Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, provides superior glycemic control and weight loss compared to GLP-1 receptor agonists alone, while offering cardioprotective benefits through lipid lowering and anti-inflammatory mechanisms.
Tirzepatide is a once-weekly injection that activates two gut hormones (GIP and GLP-1) to lower blood sugar, reduce appetite, and protect the heart. It is more effective than older GLP-1 drugs for weight loss and blood sugar control. Start with a low dose to minimize stomach upset, and work with your doctor to find the right dose for you.
In the SURPASS-2 trial, tirzepatide demonstrated superior reductions in HbA1c and body weight compared to the GLP-1RA semaglutide... tirzepatide has lipid-lowering effects, reducing total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglyceride levels, while increasing high-density lipoprotein cholesterol (HDL-C)... it suppresses the expression of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6)...
Why this rating
Based on multiple clinical trials (SURPASS-1 to -5) and mechanistic studies.
Source
Pharmacogenomics of Tirzepatide: Genomic Insights into Dual GIP/GLP-1 Agonist Response in Type 2 Diabetes and Atherosclerosis
Zihang Song et al. · Pharmaceuticals · 2025
DOI 10.3390/ph18091261
More from this paper
- Genetic variants in GLP1R (e.g., rs6923761), GIPR (e.g., rs2287019, rs10423928), and TCF7L2 (rs7903146) significantly influence individual response to tirzepatide, affecting glycemic control, weight loss, and side effect profiles.Moderate
- Tirzepatide may reduce the risk of atherosclerosis progression through lipid-lowering, anti-inflammatory, and improved insulin sensitivity mechanisms, offering cardioprotective benefits beyond glycemic control.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →